AbbVie reported 2025 first-half revenue of USD 28.8 billion, up 7.4%, powered by immunology drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib), which collectively generated USD 11.6 billion after 57% increase over 2024. Skyrizi reached USD 7.8 billion (+66%) while Rinvoq hit USD 3.7 billion (+49%), eclipsing legacy blockbuster Humira (adalimumab), which fell 55% to USD 2.3 billion amid biosimilar competition. The company's neuroscience portfolio grew 20% to USD 5 billion, led by schizophrenia drug Vraylar (cariprazine) at USD 1.7 billion.

Oncology revenue rose 4% to USD 3.3 billion, with newly acquired FRα ADC Elahere (mirvetuximab soravtansine) jumping 76% to USD 338 million. AbbVie expanded its pipeline through 10 deals in 2025, including USD 1.9 billion for CD3/BCMA/CD38 trispecific ISB 2001. CEO Robert Michael highlighted "diversified growth platforms" as the driver behind raised full-year guidance, with telisotuzumab vedotin, the first c-Met ADC, launching in May to target lung cancer.

According to PharmCube's NextBiopharm® database, AbbVie's former top-seller Humira has seen its sales drop to 2012 levels after peaking in 2022 before the arrival of biosimilars. Click here to request a free trial for NextBiopharm®.